Chronic myelogenous leukemia (CML) results from a t (9, 22) 
INTRODUCTION
CML, a diagnosis given for 15 % of adult leukemias, represents a clonal expansion of granulocytic progenitor cells (1) . CML is caused by a reciprocal t(9;22) translocation of c-abl from chromosome 9 to the breakpoint cluster region (bcr) gene on chromosome 22 (1;2) . In 95 % of CML cases, translocation involves the major bcr, leading to generation of the 210 kDa BCR-ABL fusion oncoprotein (p210 BCR-ABL ). A similar BCR-ABL translocation is also be found in 20-30 % of cases of adult acute lymphoblastic leukemia (ALL) and 5 % of childhood ALL (3;4). In both cases, the serine-threonine kinase domain from BCR partially replaces the inhibitory NH 2 -terminal SH 3 domain of ABL, producing a fusion protein with constitutive ABL tyrosine kinase activity (3;5;6).
Dysregulated BCR-ABL signaling induces pleiotropic phenotypic changes in granulocytic cells, including resistance to chemotherapy-induced apoptosis, disruption of cell cycle checkpoints, induction of growth factor-independent proliferation (7), cellular transformation in vitro (3) , and production of a CML-like leukemia in vivo (8;9) . Moreover, BCR-ABL signaling is required to actively maintain cellular viability. For example, downregulation of BCR-ABL expression (10;11) or inhibition of its ABL tyrosine kinase activity using the 2-phenlyaminopyridmidine inhibitor, imatinib (STI571) induces apoptosis in vitro and remissions during the chronic phase of CML in the clinic (10;12) . A body of work has shown that BCR-ABL regulates diverse signaling pathways including p21 ras , PI3 kinase, protein kinase C [PKC, (13) ], Jak-STAT (3;14) , and NF-κB (15;16) . The relationships of these signaling pathways to specific cellular responses are still being elucidated. Perhaps best understood is the p21 ras /Raf pathway in mediating cellular transformation by BCR-ABL. Inhibition of p21 ras , either by administration of antisense oligonucleotides or microinjection of blocking antibodies, prevents expression of the c-myc proto-oncogene, thereby blocking cellular transformation
[reviewed in (17) ].
A hallmark of BCR-ABL-expressing cells is the profound resistance to chemotherapeutic agent-induced apoptosis (13;16;18;19) . Chemotherapy-induced cell death involves proteolytic cleavage of cysteine proteases, called caspases, whose activation can be triggered by cytochrome c release from mitochondria (20) . In the cytosol, cytochrome c binds apoptotic protease activation factor (Apaf) -1, inducing its oligomerization to form the "apoptosome" (21) , an enzymatically competent Apaf-1/procaspase-9 complex that cleaves procaspase -3, thereby committing the cell to autolysis.
BCR-ABL causes chemotherapy resistance, at least in part, by interfering with the caspase activation pathway at multiple steps. Previous studies have shown that Ph+ cells isolated either during CML blast crisis or after ectopic BCR-ABL expression release diminished amounts of cytochrome c into the cytosol after exposure to high dose Ara-C or etoposide (22;23) .
At the biochemical level, BCR-ABL transformed cells express increased amounts of the outer mitochondrial membrane protein Bcl-x L which prevents Bax insertion into the outer mitochrondial membrane, reducing chemotherapy-induced cytochrome c release (23) . In addition, we have recently shown that BCR-ABL signaling through the PKCι−NF-κB pathway is also required for resistance to paclitaxel (Taxol)-induced apoptosis (16) . NF-κB is an inducible transcription factor that activates expression of several inhibitors of apoptosis (IAP) proteins, polypeptides that bind and inactivate caspases as well as inducing ubiquitin-mediated degradation of the RHG proteins [Reaper, HID, and Grim, Ref (24) ]. Together these findings suggest that BCR-ABL may induce chemotherapy resistance by controlling expression of proteins that antagonize caspase activation at multiple points.
Several studies have begun to identify BCR-ABL activated genomic programs, focusing on BCR-ABL activated genes important in cell cycle regulation or molecular signatures (25) (26) (27) .
However, whether BCR-ABL activates other genetic targets controlling anti-apoptosis has not been completely resolved. Here we apply discovery-based tools to investigate the effects of For each gene, local background was subtracted from the total hybridization intensity and the average signal intensity determined for duplicate spots. To compare differences in gene expression between arrays, background subtracted average intensity was normalized that of housekeeping genes. Only those genes which showed an average 3.5-fold upregulation or downregulation across duplicate membranes were further considered.
High density oligonucleotide arrays-Four independent RNA samples were prepared from the HL-60/Neo and the HL-60/BCR-ABL transfected cells for hybridization to the Hu95A
GeneChip (Affymetrix, Santa Clara, CA). First-strand cDNA synthesis was performed using total RNA (10-25 µg), a T7 -(dT) 24 oligomer and SuperScript II reverse transcriptase (Life Technologies). Second strand synthesis, target RNA labeling and hybridization were as previously described (34) . Gene Chip arrays were scanned using a Gene Array Scanner (Hewlett Packard) and analyzed using the Gene Chip Analysis Suite 4 software (Affymetrix Inc). The average difference statistic was retrieved for quantification of mRNA abundance in those samples in which the absolute call indicated that the gene was present.
Oligonucleotide Microarray Data analysis-Reproducibility of the four independent microarrays was determined by calculating the correlation coefficient for the log-transformed average difference values for the probe sets in each array (34) . For each pairwise comparison, the mean correlation coefficient was 0.945 ± 0.024 (n = 6) in the HL-60/Neo data sets, and 0.977 ± 0.010 ( n = 6 ) for the HL-60/BCR-ABL data sets, indicating that the measurements were highly reproducible ( Table I ) Northern blot analysis-RNA was isolated from K562, HL-60 Neo and HL-60 BCR-ABL cells using RNAqueous (Ambion). 20µg of total RNA was fractionated by electrophoresis on a denaturing formaldehyde 1% agarose gel (13), transferred to BrightStar membrane (Ambion) and immobilized by UV crosslinking. Full length, linearized Hsp70 cDNA, GAPDH control probe (Ambion), and 18S rRNA control probes were radiolabeled with 32 P using the X kit (Amersham), hybridized and washed (13) .
Western blot analysis-Western blots were performed as described previously (13) .
Briefly, cells were counted and equal numbers were harvested and lysed directly into Laemmli Luciferase reporter activity was normalized to the internal control of β-galactosidase activity to control for differences in transfection efficiency. ANOVA. This analysis identified 487 unique genes whose expression was changed by BCR-ABL at a p value [Pr(F)] of <0.001 (293 were upregulated) and 36 at p<0.000001 (22 were upregulated). These latter genes were classified by primary biochemical function (Table III) .
Electrophoretic Mobility Shift Assay (EMSA)-

RESULTS
Identification of genes downstream of the BCR-ABL pathway-
The most highly regulated group included the pim-1 oncogene, signaling kinases (a guanine A role for GATA in regulation of Hsp70 expression has not been described previously.
To determine its function within the Hsp 70 promoter in p210 BCR-ABL dependent transactivation, a mutation was introduced into the core GATA sequence in the -123/+37 Hsp70 reporter (Fig.   6A) ; the resulting construct was tested for the BCR-ABL inducibility. As seen in Fig. 6D , the Hsp 70 promoter containing the GATA site mutation was not induced by p210 , and to a similar degree (6-fold) in its presence (Fig. 6E ). These two stimuli together produced a 67-fold induction of reporter activity, resulting in an absolute magnitude that was clearly greater than that produced by the sum of either stimulus alone, representing a greater than additive response. Together, these data indicate that the GATA response element was essential for p210 BCR-ABL induced transactivation of the Hsp70 promoter and functioned in a pathway independent from that induced by heat shock on the HSE. (Fig. 7B) . Addition of anti-GATA-1 antibody produced a strong supershift, depleting over 50 % of the specific GATA binding complex.
BCR-ABL transactivates
Nuclear extracts from the Ph+ K562 cells exhibited a similar supershift indicating that GATA-1 is also the major GATA binding species of the Hsp70 promoter in CML cells (Fig. 7B, lanes   5,6) . Finally, to establish that the GATA response element was a bone fide p210
BCR-ABL -inducible enhancer, multimeric copies of the GATA WT or GATA Mut DNA binding sequences were ligated upstream of an inert TATA-driven luciferase reporter and assessed for p210 BCR-ABL responsiveness. We found that the GATA WT sequences were potently induced by p210
BCR-ABL over a wide concentration range whereas the GATA Mut was poorly induced (Fig. 7C) .
Because of differences in the NH 2 -terminal serine-threonine kinase Bcr domain, p185
BCR-ABL induces a distinct pattern of intracellular signaling and a phenotypically-distinct spectrum of leukemias (3;4) compared to p210 BCR-ABL (14) . To determine whether activation of GATA RE was common to both BCR-ABL oncoproteins, we tested whether the same response element could also be transactivated by p185 BCR-ABL . As seen in Fig. 8 , both BCR-ABL oncoproteins potently transactivated the GATA multimer. Together these indicate that Hsp 70 transactivation through the GATA RE is a shared feature of the BCR-ABL oncoproteins.
siRNA mediated knockdown of Hsp70 expression sensitized K562 cells to paclitaxelinduced apoptosis-To assess the contribution of Hsp70 expression in the chemotherapeutic agent resistant phenotype, we performed siRNA-mediated "knockdown" of Hsp70. As seen in 
DISCUSSION
The constitutively active p210 BCR-ABL oncoprotein produces CML (9), confers growth factor-independent proliferation (7) and produces resistance to chemotherapy-induced apoptosis through largely unknown mechanisms at the genetic level. Our study adds to the work of others that indicate p210 BCR-ABL controls expression of multiple genes in common biochemical pathways that are relevant to leukemogenesis (25) (26) (27) . (Table II) . Likewise, the binding target of γ catenin/plakoglobin, α catenin, is also strongly upregulated in both microarray experiments (Tables II, III to -58. This site primarily binds the GATA-1 isoform in CML cells. The observation that mutation of the GATA-RE renders the Hsp70 promoter unresponsive to p210 BCR-ABL , along with the finding that a multimeric GATA-RE is sufficient to confer BCR-ABL inducibility to an inert promoter strongly support the conclusion that this regulatory site is a bone fide BCR-ABL target.
GATA-1 is a zinc finger containing transcription factor that plays a central role in development of erythrocytes and megakaryocytes. This transcription factor is required for expression of globin, heme biosynthesis and RBC transcription factor genes (43). In GATA-1 -/-mice, erythroid precursors undergo maturation arrest and apoptosis, indicating that GATA-1 also plays a role in cellular survival (57) . Table III for gene identities). Table I 27
